Malta - English - Medicines Authority

genzyme europe bv paasheuvelweg 25, 1105 bp amsterdam , netherlands - fludarabine phosphate - film-coated tablet - fludarabine phosphate 10 mg - antineoplastic agents

Malta - English - Medicines Authority

genzyme europe bv paasheuvelweg 25, 1105 bp amsterdam , netherlands - rabbit immunoglobulin - powder for solution for infusion - rabbit immunoglobulin 25 mg - immunosuppressants

Ireland - English - HPRA (Health Products Regulatory Authority)

genzyme europe b.v. - fludarabine phosphate - powder for solution for injection/infusion - 50 milligram(s) - purine analogues; fludarabine

Malta - English - Medicines Authority

genzyme europe bv paasheuvelweg 25, 1105 bp amsterdam , netherlands - fludarabine phosphate - powder for solution for infusion or injection - fludarabine phosphate 25 mg/ml - antineoplastic agents

Ireland - English - HPRA (Health Products Regulatory Authority)

genzyme europe b.v. - rabbit anti-human thymocyte immunoglobulin - powder for solution for infusion - 25 milligram(s) - selective immunosuppressants; antithymocyte immunoglobulin (rabbit)

Ireland - English - HPRA (Health Products Regulatory Authority)

genzyme europe b.v. - fludarabine phosphate - film-coated tablet - 10 milligram(s) - purine analogues; fludarabine

European Union - English - EMA (European Medicines Agency)

sanofi b.v. - sevelamer - renal dialysis; hyperphosphatemia - all other therapeutic products - renagel is indicated for the control of hyperphosphataemia in adult patients receiving  haemodialysis or peritoneal dialysis.renagel should be used within the context of a multiple therapeutic approach, which could include calcium supplements, 1,25 - dihydroxy vitamin d3 or one of its analogues to control the development of renal bone disease.

European Union - English - EMA (European Medicines Agency)

sanofi b.v. - imiglucerase - gaucher disease - other alimentary tract and metabolism products, - cerezyme (imiglucerase) is indicated for use as longterm enzyme replacement therapy in patients with a confirmed diagnosis of non-neuronopathic (type 1) or chronic neuronopathic (type 3) gaucher disease who exhibit clinically significant nonneurological manifestations of the disease. the non-neurological manifestations of gaucher disease include one or more of the following conditions:anaemia after exclusion of other causes, such as iron deficiencythrombocytopeniabone disease after exclusion of other causes such as vitamin d deficiencyhepatomegaly or splenomegaly

European Union - English - EMA (European Medicines Agency)

sanofi b.v. - sevelamer carbonate - hyperphosphatemia; renal dialysis - all other therapeutic products - renvela is indicated for the control of hyperphosphataemia in adult patients receiving haemodialysis or peritoneal dialysis.renvela is also indicated for the control of hyperphosphataemia in adult patients with chronic kidney disease not on dialysis with serum phosphorus ≥ 1.78 mmol/l.renvela should be used within the context of a multiple therapeutic approach, which could include calcium supplement, 1,25-dihydroxy vitamin d3 or one of its analogues to control the development of renal bone disease.

European Union - English - EMA (European Medicines Agency)

sanofi b.v. - agalsidase beta - fabry disease - other alimentary tract and metabolism products, - fabrazyme is indicated for long-term enzyme replacement therapy in patients with a confirmed diagnosis of fabry disease (α-galactosidase-a deficiency).